Adagio Medical Faces Nasdaq Minimum Bid Price Noncompliance
TipRanks (Fri, 12-Jun 6:50 PM ET)
Business Wire (Thu, 21-May 8:00 AM ET)
Adagio Medical Reports First Quarter 2026 Results and Meaningful Clinical Progress
Business Wire (Tue, 12-May 8:05 AM ET)
Adagio Medical to Participate in the BofA Securities 2026 Health Care Conference
Business Wire (Wed, 29-Apr 8:00 AM ET)
Adagio Medical Announces Positive Pivotal Results for vCLAS Ventricular Ablation System
Business Wire (Sun, 26-Apr 9:32 AM ET)
Adagio Medical's ULTA Technology to Be Featured at the Heart Rhythm 2026 Conference
Business Wire (Thu, 16-Apr 8:00 AM ET)
Business Wire (Wed, 8-Apr 8:00 AM ET)
Adagio Medical to Participate in the 25th Annual Needham Virtual Conference
Business Wire (Mon, 6-Apr 8:00 AM ET)
Business Wire (Wed, 1-Apr 8:00 AM ET)
Adagio Medical Reports Fourth Quarter and Full Year 2025 Results
Business Wire (Fri, 27-Mar 8:00 AM ET)
Adagio Medical Holdings Inc is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias with its proprietary, catheter-based Ultra-Low Temperature Ablation (ULTA) technology. UTLA is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The company is currently focused on the treatment of ventricular tachycardia (VT), a rapid, abnormal heart rhythm, or arrhythmia, that originates in the heart's lower chambers, or ventricles. The company has one reportable segment.
Adagio Medical Holdings trades on the NASDAQ stock market under the symbol ADGM.
As of June 12, 2026, ADGM stock price declined to $0.75 with 46,115 million shares trading.
ADGM has a beta of 0.92, meaning it tends to be less sensitive to market movements. ADGM has a correlation of 0.01 to the broad based SPY ETF.
ADGM has a market cap of $16.55 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that ADGM belongs to (by Net Assets): VXF, VTI.
ADGM has underperformed the market in the last year with a return of -36.9%, while the SPY ETF gained +24.1%. In the last 3 month period, ADGM fell short of the market, returning -27.0%, while SPY returned +11.6%. However, in the most recent 2 weeks ADGM has outperformed the stock market by returning +2.9%, while SPY returned -1.9%.
ADGM support price is $.72 and resistance is $.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADGM shares will trade within this expected range on the day.